The application segment of the Oligonucleotide Synthesis Linkers market is driven primarily by three distinct use‑cases: therapeutic oligonucleotides, diagnostic assays, and research‑grade tools. Therapeutic applications—encompassing antisense, siRNA, and CRISPR‑based modalities—account for the largest share, reflecting high‑value clinical pipelines and substantial investment in personalized medicine. Diagnostic assays, particularly those targeting infectious disease markers and oncology biomarkers, contribute a growing portion as regulatory approvals increase and point‑of‑care testing expands. Research‑grade tools, used in academic and contract‑research laboratories for gene‑function studies and assay development, sustain a stable baseline demand. Collectively, these sub‑segments define the overall market size, with therapeutic linkers delivering premium pricing, diagnostics offering volume‑driven growth, and research maintaining consistent consumption. This nuanced Oligonucleotide Synthesis Linkers segmentation underscores how application diversity buffers the market against volatility in any single end‑use.